SELEXIS
Selexis is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients.
SELEXIS
Industry:
Biotechnology Health Diagnostics
Founded:
2001-01-01
Address:
Plan-les-ouates, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.selexis.com
Total Employee:
11+
Status:
Active
Contact:
(022) 308-9360
Email Addresses:
[email protected]
Total Funding:
67.48 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome
Current Employees Featured
Founder
Investors List
Eurostars
Eurostars investment in Grant - Selexis
Foundation for Technological Innovation (FIT)
Foundation for Technological Innovation (FIT) investment in Debt Financing - Selexis
Newest Events participated




Official Site Inspections
http://www.selexis.com
- Host name: 199.60.103.166
- IP address: 199.60.103.166
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto

More informations about "Selexis"
JSR Life Sciences Announces Operational Consolidation โฆ
May 31, 2023 KBIโs new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers Sunnyvale, Calif. -- (May 31, 2023) -- JSR Life Sciences today announced that โฆSee details»
Selexis - Crunchbase Company Profile & Funding
Selexis is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the โฆSee details»
KBI Biopharma, Selexis SA Merge as One Organization
Jun 5, 2023 and Selexis SA, a cell line development company, are consolidating as one organization under the KBI Biopharma name. The fusion is expected to enable integrated, solutions for customers, cell line development through โฆSee details»
Press Release | JSR Life Sciences Agrees to Acquire Pioneering Cell ...
Jun 14, 2017 About Selexis SA Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing โฆSee details»
Selexis SA - Crunchbase Company Profile & Funding
Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.See details»
KBI Biopharma and Selexis Hold Joint Ribbon Cutting โฆ
Jul 6, 2022 The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies. GENEVA, Switzerland, July 6, 2022 โ KBI Biopharma SA (KBI) โฆSee details»
Selexis SA - Plan-les-Ouates, Switzerland
Selexis is a science-driven organization, founded on the academic interests and discoveries of its core scientific team in molecular biology, cellular physiology, and genetic engineering, and is โฆSee details»
Selexis 2025 Company Profile: Valuation, Investors, โฆ
Information on acquisition, funding, cap tables, investors, and executives for Selexis. Use the PitchBook Platform to explore the full profile.See details»
Selexis SA - VentureRadar
Swiss-based Selexis SA is a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development. ... Find out more about Selexis SA, Biotech, โฆSee details»
Selexis SA - Drug pipelines, Patents, Clinical trials - Synapse
Selexisโ proprietary cell line development platform will be branded as the SUREtechnology Platform. Mowery will continue to lead as CEO of the combined organization.See details»
Selexis Company Profile - Office Locations, Competitors ... - Craft
See insights on Selexis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
JSR Life Sciences Announces Operational Consolidation of KBI โฆ
Sunnyvale, Calif. โ (May 31, 2023) โ JSR Life Sciences today announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization under the KBI Biopharma โฆSee details»
Selexis - Products, Competitors, Financials, Employees, โฆ
Selexis is a biotech company that specializes in mammalian (suspension-adapted CHO-K1) cell line generation. It specializes in drug discovery, cell line development, and biopharmaceutical โฆSee details»
Selexis and KBI Biopharma Enter into Agreements with Immatics โฆ
Jun 30, 2021 About Selexis SA Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions โฆSee details»
Selexis S.A. - Great Place To Work
Selexis S.A. - Our cell line development timelines and innovation are unprecedented. This is our focus, which is why we do it best. Ultimately, we help companies get drugs to patients faster โฆSee details»
Delving into the Latest Updates on Selexis SA with Synapse
Selexisโ proprietary cell line development platform will be branded as the SUREtechnology Platform. Mowery will continue to lead as CEO of the combined organization.See details»
Mark Womack - CEO at Selexis | The Org
An organization builder with a track record of delivering unprecedented growth and profit in every role, Mark Womack is the Chief Executive Officer of Selexis. Before joining Selexis, Mark โฆSee details»
Selexis - Contacts, Employees, Board Members, Advisors & Alumni
Selexis has 5 current employee profiles, including VP, Licensing and Business Development Yemi Onakunle.Selexis is a pioneering life science company.See details»
Selexis SA: Drug pipelines, Patents, Clinical trials - Synapse
May 28, 2023 Explore Selexis SA with its drug pipeline, therapeutic area, technology platform, 26 news, and 5 literature.See details»
Selexis โ Swiss Biotech
The advanced technologies in protein expression by Selexis provide biotech and pharmaceutical companies with a rapid, stable, and cost-effective solution for the production of recombinant โฆSee details»